从HBV特异性免疫细胞角度谈慢性乙型肝炎功能性治愈  

Functional cure of chronic hepatitis B from the perspective of specific immune cells for hepatitis B virus

作　　者：刘小菊 张政 LIU Xiaoju;ZHANG Zheng(National Clinical Research Center for Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen, Guangdong 518112, China)

机构地区：[1]国家感染性疾病临床医学研究中心(深圳市第三人民医院),广东深圳518112 [2]南方医科大学南方医院感染科,广州510515

出　　处：《临床肝胆病杂志》2020年第5期977-979,共3页Journal of Clinical Hepatology

摘　　要：慢性乙型肝炎(CHB)患者实现功能性治愈代表患者获得了持久的病毒学抑制和免疫学控制,是目前国内外最新CHB防治指南推荐的理想治疗目标。CHB患者长期直接抗病毒治疗可获得病毒学抑制,但仅有极少数患者能获得功能性治愈,提示迫切需要抗病毒药物和免疫治疗的联合疗法。目前最佳治疗策略是靶向精准清除HBV感染的肝细胞,减少肝组织损伤;但这依赖于肝脏中HBV特异性免疫细胞。因此恢复或增强HBV特异性T淋巴细胞和B淋巴细胞的功能是实现CHB功能治愈的关键策略。Functional cure of chronic hepatitis B(CHB)marks sustained virological inhibition and immunological control and is the ideal treatment goal recommended by the latest guidelines for the prevention and treatment of CHB in China and foreign countries.CHB patients can achieve virological inhibition with the help of long-term direct antiviral therapy,and only a small number of patients can achieve functional cure,suggesting that there is an urgent need for the combination of direct antiviral therapy and immunotherapy.At present,the best treatment strategy is targeted precise clearance of HBV-infected hepatocytes to reduce liver injury,which depends on HBV-specific immune cells in the liver.Therefore,restoring or enhancing the function of HBV-specific T cells and B cells is the key strategy for functional cure of CHB.

关 键 词：乙型肝炎病毒 乙型肝炎 慢性 HBV特异性T淋巴细胞 HBV特异性B淋巴细胞 

分 类 号：R512.62[医药卫生—内科学]